Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaccine stop the virus behind mono, cancer, and MS?

NCT ID NCT06655324

Vaccine Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus (EBV), which can cause infectious mononucleosis and is linked to certain cancers and multiple sclerosis. The study will enroll 250 healthy adults and teens to check the vaccines' safety, side effects, and ability to trigger an immune response. Participants will be randomly assigned to receive either the vaccine or a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization. * Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17. Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment. * Has any immunosuppressive medical condition or receive any immunosuppressive therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    5 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alliance for Multispecialty Research, LLC ( Site 0008)

    RECRUITING

    Kansas City, Missouri, 64114, United States

  • Alliance for Multispecialty Research, LLC ( Site 0009)

    ACTIVE_NOT_RECRUITING

    Knoxville, Tennessee, 37909, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)

    RECRUITING

    Springfield, Missouri, 65802, United States

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0011)

    COMPLETED

    Glendale, California, 91206, United States

  • Lynn Health Science Institute ( Site 0010)

    RECRUITING

    Oklahoma City, Oklahoma, 73112, United States

  • QPS-MRA, LLC ( Site 0012)

    ACTIVE_NOT_RECRUITING

    Miami, Florida, 33143, United States

  • Remington-Davis, Inc. ( Site 0017)

    RECRUITING

    Columbus, Ohio, 43215, United States

  • Velocity Clinical Research Lincoln ( Site 0004)

    RECRUITING

    Lincoln, Nebraska, 68510, United States

  • Velocity Clinical Research, Omaha ( Site 0005)

    ACTIVE_NOT_RECRUITING

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.